Picture of Elanix Biotechnologies AG logo

ELN Elanix Biotechnologies AG Share Price

0.000.00%
de flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-2.3%
3m-28.3%
6m-51.29%
1yr-69.46%
Volume Change (%)
10d/3m-91.11%
Price vs... (%)
52w High-74.75%
50d MA-13.1%
200d MA-49.6%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equity-30.78%
Operating Margin-4928.99%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 201931st Dec 2020
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2019 / 2020

Blurred out image of Elanix Biotechnologies AG EPS forecast chart

Profile Summary

Elanix Biotechnologies AG is a Germany-based provider of solutions for tissue regeneration. The Company develops and commercializes products for acute wound care, dermatological and gynecological applications, and also provides cell technology services. It develops bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts. The Company's product portfolio comprises Gyn-RepAir cream, which contains a Cell Free Protein Complex (CFPC), and which includes various proteins such as collagen and fibronectin, as well as RepAir-A N cream. The Company also produces validated progenitor skin cells used in drug discovery, toxicity testing and cosmetic applications. It is a spin-out from the University Hospital of Lausanne (CHUV) in Switzerland.

Directors

    Last Annual
    December 31st, 2018
    Last Interim
    June 30th, 2019
    Incorporated
    March 26th, 1997
    Public Since
    November 16th, 1998
    Sector
    Biotechnology & Medical Research
    Industry
    Healthcare
    Exchange
    de flag iconFrankfurt Stock Exchange
    Shares in Issue
    8,080,902

    ELN Share Price Performance

    Upcoming Events for ELN

    Similar to ELN

    Picture of 4Sc AG logo

    4Sc AG

    de flag iconFrankfurt Stock Exchange

    Picture of CureVac NV logo

    CureVac NV

    de flag iconFrankfurt Stock Exchange

    Picture of Deutsche Biotech Innovativ AG logo

    Deutsche Biotech Innovativ AG

    de flag iconFrankfurt Stock Exchange

    Picture of Diagonal Bio AB logo

    Diagonal Bio AB

    de flag iconFrankfurt Stock Exchange

    Picture of Medpace Holdings logo

    Medpace Holdings

    de flag iconFrankfurt Stock Exchange

    FAQ